Biotech firms with a strong pipeline of upcoming FDA approvals and a history of successful drug launches.

Here are Biotech firms with a strong pipeline of upcoming FDA approvals and a history of successful drug launches. The details are as follows: 1. **Moderna**: - Upcoming FDA approval for RSV. - Potential for expanded approval of Abecma in less pre-treated patients. - Approval of KarXT in schizophrenia anticipated. 2. **Ultragenyx**: - Breakthrough Therapy Designation for GTX-102 in Angelman syndrome. - Expected to launch in 2025. 3. **SineuGene**: - FDA Orphan Drug Designation for SNUG01 in ALS. - Gene therapy targeting TRIM72, showing neuroprotection. 4. **Hemispherian**: - Orphan Drug Designation for GLIX1 in malignant glioma. - Targets DNA repair vulnerabilities in cancer cells. These companies demonstrate a promising pipeline of drugs approaching FDA approval, along with a track record of successful drug launches.